This is the authors' abstract. We don't add key points for this paper.
We estimated the effectiveness of booster doses of monovalent and bivalent mRNA COVID-19 vaccines against Omicron-associated severe outcomes among adults aged ≥50 years in Ontario, Canada. Monovalent and bivalent mRNA COVID-19 booster doses provided similar strong initial protection against severe outcomes. Uncertainty remains around waning of protection from these vaccines.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Grewal et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: